Sanofi to terminate haemophilia development pact with Oxford Biomedica

(Alliance News) - Oxford Biomedica PLC on Friday said Sanofi SA intends to terminate the ...

Alliance News 19 March, 2021 | 10:29AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Oxford Biomedica PLC on Friday said Sanofi SA intends to terminate the collaboration and license agreement between the two firms in the field of haemophilia gene therapy.

Oxford Biomedica had originally signed the pact for process development and manufacturing of lentiviral vectors to treat haemophilia with Bioverativ, which was acquired by French pharmaceutical firm Sanofi, in February 2018.

"The group expects that the impact on revenue will be negligible over the coming 24 month period," Oxford Biomedica said.

Shares in gene and cell therapy company Oxford Biomedica were down 2.7% at 994.00 pence in London on Friday.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Oxford BioMedica PLC 220.00 GBX 0.69 -
Sanofi SA 91.62 EUR 4.47

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures